<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591616</url>
  </required_header>
  <id_info>
    <org_study_id>TP73</org_study_id>
    <nct_id>NCT01591616</nct_id>
  </id_info>
  <brief_title>Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel</brief_title>
  <official_title>A Phase 4 Pediatric Study to Assess the Pharmacokinetics and Safety of Oraqix Gel in Healthy Children and Adolescent Volunteers Following Tooth Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dentsply International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dentsply International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish Oraqix is safe when used on adolescent volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, uncontrolled, open-label, single administration patient study. Male
      and female subjects aged 6 through 17 years of age in need of primary tooth extraction will
      be recruited from the Principal Investigator's database and may be supplemented by
      advertising. Subjects who withdraw from the study prematurely will be replaced.

      Subjects will undergo an initial screening visit at which eligibility will be determined.
      After completion of informed consent/assent a physical examination, vitals, 12-lead ECG, and
      dental examination will be conducted. A medical history will be documented and a blood sample
      will be collected for analysis of biochemistry, hematology and as appropriate, serum
      pregnancy assessment for females.

      Subjects will return to the office approximately 1 to 10 days after Visit 1 for Visit 2. At
      Visit 2, study treatment will be administered and PK blood samples will be collected for
      analysis, and monitored for safety parameters. Up to a total of five cartridges of OraqixÂ®
      will be administered to the oral cavity in the area of the tooth extraction, based on the
      body weight of the subject. No more than five cartridges will be dispensed, since this is the
      maximum dose for this agent. The final sample will be collected 4 hours after administration
      of study material. An abbreviated dental examination will be conducted, any adverse events
      (AEs) will be documented and the subject will be discharged from the clinic.

      All subjects will be contacted by telephone approximately 24 hours after administration of
      study treatment. Study personnel will enquire about the occurrence of any AEs that have
      occurred since leaving the office. If appropriate, further follow-up of AEs will be arranged.
      In the absence of any ongoing AEs requiring follow up the subject will be considered to have
      completed the study at the completion of the telephone call.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>5, 10, 15, 30, 60, 90, 120, and 240 minutes</time_frame>
    <description>The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>blood draws pre-dose, 2 and 4 hours postdose</time_frame>
    <description>The % MetHb levels and vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
ECG taken at pre-dose and 1, 2 and 4h post dose, measurement of heart rate and PR, QRS, QT and QTcB intervals.
Visual analogue scale conducted at pre-dose (immediately before Oraqix administration), immed. post extraction, at 0.25, 0.5, 1 and 2h post dose and prior to discharge just after 4h post dose.
For each subject, phone call was made at +24h as follow up pursuant to the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs (Pulse)</measure>
    <time_frame>Pre-dose and every 10 minute to 240 minutes post-dose.</time_frame>
    <description>Vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs (Systolic Pressure)</measure>
    <time_frame>Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs (Diastolic Pressure)</measure>
    <time_frame>Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs (Ventricular Heart Rate)</measure>
    <time_frame>Pre-dose, 1 hour, 2 hour, 4 hour post-dose.</time_frame>
    <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs (PR Interval)</measure>
    <time_frame>Pre-dose, 1 hour, 2 hour, 4 hour post-dose.</time_frame>
    <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs (QRS Duration)</measure>
    <time_frame>Pre-dose, 1 hour, 2 hour, 4 hour post-dose.</time_frame>
    <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs (QT Interval)</measure>
    <time_frame>Pre-dose, 1 hour, 2 hour, 4 hour post-dose.</time_frame>
    <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs (QTcB Interval)</measure>
    <time_frame>Pre-dose, 1 hour, 2 hour, 4 hour post-dose.</time_frame>
    <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Periodontal Disease</condition>
  <arm_group>
    <arm_group_label>Oraqix for tooth extraction</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine and prilocaine</intervention_name>
    <description>Appropriate dose of Oraqix based on weight will be given before tooth extraction</description>
    <arm_group_label>Oraqix for tooth extraction</arm_group_label>
    <other_name>Oraqix periodontal gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 and 17 and eleven twelfths

          -  requires tooth extraction

          -  healthy having not taken any prescription or over the counter medications within 60
             days of first visit

          -  must be a minimum of 15 kg

        Exclusion Criteria:

          -  anesthesia required for treatment other than study material

          -  given blood within 90 days of first visit

          -  pregnant

          -  allergic to local anesthetic

          -  documented history of glucose-6-phosphate dehydrogenase deficiency

          -  history of congenital idiopathic methemoglobinemia

          -  does not have a loose tooth easily extracted or who, in the opinion of the
             Investigator, is not suitable for tooth extraction using only topical anesthetic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tegwyn Brickhouse, D.D.S PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonweath School of Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonweath School of Dentistry</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <results_first_submitted>February 20, 2014</results_first_submitted>
  <results_first_submitted_qc>February 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 3, 2014</results_first_posted>
  <last_update_submitted>February 20, 2014</last_update_submitted>
  <last_update_submitted_qc>February 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Gingival Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
    <mesh_term>EMLA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oraqix for Tooth Extraction</title>
          <description>lidocaine and prilocaine: Appropriate dose of Oraqix based on weight will be given before tooth extraction</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oraqix for Tooth Extraction</title>
          <description>lidocaine and prilocaine: Appropriate dose of Oraqix based on weight will be given before tooth extraction</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics</title>
        <description>The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).</description>
        <time_frame>5, 10, 15, 30, 60, 90, 120, and 240 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Cmax</title>
          </group>
          <group group_id="O2">
            <title>Prilocaine Cmax</title>
          </group>
          <group group_id="O3">
            <title>2,6-xylidine Cmax</title>
          </group>
          <group group_id="O4">
            <title>O-toluidine Cmax</title>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics</title>
          <description>The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9" spread="66"/>
                    <measurement group_id="O2" value="41.8" spread="60.6"/>
                    <measurement group_id="O3" value="3.72" spread="48.5"/>
                    <measurement group_id="O4" value="5.13" spread="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <description>The % MetHb levels and vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
ECG taken at pre-dose and 1, 2 and 4h post dose, measurement of heart rate and PR, QRS, QT and QTcB intervals.
Visual analogue scale conducted at pre-dose (immediately before Oraqix administration), immed. post extraction, at 0.25, 0.5, 1 and 2h post dose and prior to discharge just after 4h post dose.
For each subject, phone call was made at +24h as follow up pursuant to the protocol.</description>
        <time_frame>blood draws pre-dose, 2 and 4 hours postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>% MetHemoglobin (MetHb) Time Point -20 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O2">
            <title>% MetHemoglobin (MetHb) Time Point -10 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O3">
            <title>% MetHemoglobin (MetHb) Time Point 0 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O4">
            <title>% MetHemoglobin (MetHb) Time Point 10 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O5">
            <title>% MetHemoglobin (MetHb) Time Point 20 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O6">
            <title>% MetHemoglobin (MetHb) Time Point 30 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O7">
            <title>% MetHemoglobin (MetHb) Time Point 40 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O8">
            <title>% MetHemoglobin (MetHb) Time Point 50 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O9">
            <title>% MetHemoglobin (MetHb) Time Point 60 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O10">
            <title>% MetHemoglobin (MetHb) Time Point 70 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O11">
            <title>% MetHemoglobin (MetHb) Time Point 80 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O12">
            <title>% MetHemoglobin (MetHb) Time Point 90 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O13">
            <title>% MetHemoglobin (MetHb) Time Point 100 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O14">
            <title>% MetHemoglobin (MetHb) Time Point 110 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O15">
            <title>% MetHemoglobin (MetHb) Time Point 120 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O16">
            <title>% MetHemoglobin (MetHb) Time Point 130 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O17">
            <title>% MetHemoglobin (MetHb) Time Point 140 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O18">
            <title>% MetHemoglobin (MetHb) Time Point 150 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O19">
            <title>% MetHemoglobin (MetHb) Time Point 160 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O20">
            <title>% MetHemoglobin (MetHb) Time Point 170 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O21">
            <title>% MetHemoglobin (MetHb) Time Point 180 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O22">
            <title>% MetHemoglobin (MetHb) Time Point 190 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O23">
            <title>% MetHemoglobin (MetHb) Time Point 200 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O24">
            <title>% MetHemoglobin (MetHb) Time Point 210 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O25">
            <title>% MetHemoglobin (MetHb) Time Point 220 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O26">
            <title>% MetHemoglobin (MetHb) Time Point 230 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
          <group group_id="O27">
            <title>% MetHemoglobin (MetHb) Time Point 240 Minutes</title>
            <description>The % MetHb levels were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>The % MetHb levels and vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.
ECG taken at pre-dose and 1, 2 and 4h post dose, measurement of heart rate and PR, QRS, QT and QTcB intervals.
Visual analogue scale conducted at pre-dose (immediately before Oraqix administration), immed. post extraction, at 0.25, 0.5, 1 and 2h post dose and prior to discharge just after 4h post dose.
For each subject, phone call was made at +24h as follow up pursuant to the protocol.</description>
          <units>Percentage MetHb</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="16"/>
                <count group_id="O9" value="16"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="16"/>
                <count group_id="O13" value="16"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="16"/>
                <count group_id="O16" value="16"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="15"/>
                <count group_id="O19" value="15"/>
                <count group_id="O20" value="15"/>
                <count group_id="O21" value="15"/>
                <count group_id="O22" value="15"/>
                <count group_id="O23" value="15"/>
                <count group_id="O24" value="15"/>
                <count group_id="O25" value="15"/>
                <count group_id="O26" value="15"/>
                <count group_id="O27" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.24"/>
                    <measurement group_id="O2" value="1.3" spread="0.26"/>
                    <measurement group_id="O3" value="1.2" spread="0.20"/>
                    <measurement group_id="O4" value="1.2" spread="0.20"/>
                    <measurement group_id="O5" value="1.3" spread="0.18"/>
                    <measurement group_id="O6" value="1.5" spread="0.43"/>
                    <measurement group_id="O7" value="1.5" spread="0.20"/>
                    <measurement group_id="O8" value="1.6" spread="0.19"/>
                    <measurement group_id="O9" value="1.7" spread="0.28"/>
                    <measurement group_id="O10" value="1.7" spread="0.30"/>
                    <measurement group_id="O11" value="1.5" spread="0.35"/>
                    <measurement group_id="O12" value="1.5" spread="0.40"/>
                    <measurement group_id="O13" value="1.5" spread="0.39"/>
                    <measurement group_id="O14" value="1.6" spread="0.19"/>
                    <measurement group_id="O15" value="1.5" spread="0.32"/>
                    <measurement group_id="O16" value="1.5" spread="0.29"/>
                    <measurement group_id="O17" value="1.4" spread="0.28"/>
                    <measurement group_id="O18" value="1.4" spread="0.26"/>
                    <measurement group_id="O19" value="1.3" spread="0.34"/>
                    <measurement group_id="O20" value="1.2" spread="0.47"/>
                    <measurement group_id="O21" value="1.4" spread="0.15"/>
                    <measurement group_id="O22" value="1.4" spread="0.17"/>
                    <measurement group_id="O23" value="1.5" spread="0.20"/>
                    <measurement group_id="O24" value="1.4" spread="0.18"/>
                    <measurement group_id="O25" value="1.4" spread="0.13"/>
                    <measurement group_id="O26" value="1.5" spread="0.14"/>
                    <measurement group_id="O27" value="1.4" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics</title>
        <description>The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).</description>
        <time_frame>5, 10, 15, 30, 60, 90, 120, and 240 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Tmax</title>
          </group>
          <group group_id="O2">
            <title>Prilocaine Tmax</title>
          </group>
          <group group_id="O3">
            <title>2,6-xylidine Tmax</title>
          </group>
          <group group_id="O4">
            <title>O-toluidine Tmax</title>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics</title>
          <description>The study focused on the pharmacokinetics of prilocaine and lidocaine, o-toluidine (metabolite of prilocaine) and 2, 6-xylidine (metabolite of lidocaine). We evaluated blood samples of15 subjects at the following time points: pre-dose, at 5,10,15,30, 60, 90, 120 and 240 min post dose. We calculated Cmax (maximum observed plasma concentration) and Tmax (time to maximum plasma concentration).</description>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.0833" upper_limit="0.650"/>
                    <measurement group_id="O2" value="0.500" lower_limit="0.0833" upper_limit="0.650"/>
                    <measurement group_id="O3" value="1.50" lower_limit="0.650" upper_limit="4.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs (Pulse)</title>
        <description>Vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
        <time_frame>Pre-dose and every 10 minute to 240 minutes post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vital Signs (Pulse Rate), - 20 Minutes Pre-dose</title>
          </group>
          <group group_id="O2">
            <title>Vital Signs (Pulse Rate), - 10 Minutes Pre-dose</title>
          </group>
          <group group_id="O3">
            <title>Vital Signs (Pulse Rate), 0 Minutes Pre-dose</title>
          </group>
          <group group_id="O4">
            <title>Vital Signs (Pulse Rate), 10 Minutes Post-dose</title>
          </group>
          <group group_id="O5">
            <title>Vital Signs (Pulse Rate), 20 Minutes Post-dose</title>
          </group>
          <group group_id="O6">
            <title>Vital Signs (Pulse Rate), 30 Minutes Post-dose</title>
          </group>
          <group group_id="O7">
            <title>Vital Signs (Pulse Rate), 40 Minutes Post-dose</title>
          </group>
          <group group_id="O8">
            <title>Vital Signs (Pulse Rate), 50 Minutes Post-dose</title>
          </group>
          <group group_id="O9">
            <title>Vital Signs (Pulse Rate), 60 Minutes Post-dose</title>
          </group>
          <group group_id="O10">
            <title>Vital Signs (Pulse Rate), 70 Minutes Post-dose</title>
          </group>
          <group group_id="O11">
            <title>Vital Signs (Pulse Rate), 80 Minutes Post-dose</title>
          </group>
          <group group_id="O12">
            <title>Vital Signs (Pulse Rate), 90 Minutes Post-dose</title>
          </group>
          <group group_id="O13">
            <title>Vital Signs (Pulse Rate), 100 Minutes Post-dose</title>
          </group>
          <group group_id="O14">
            <title>Vital Signs (Pulse Rate), 110 Minutes Post-dose</title>
          </group>
          <group group_id="O15">
            <title>Vital Signs (Pulse Rate), 120 Minutes Post-dose</title>
          </group>
          <group group_id="O16">
            <title>Vital Signs (Pulse Rate), 130 Minutes Post-dose</title>
          </group>
          <group group_id="O17">
            <title>Vital Signs (Pulse Rate), 140 Minutes Post-dose</title>
          </group>
          <group group_id="O18">
            <title>Vital Signs (Pulse Rate), 150 Minutes Post-dose</title>
          </group>
          <group group_id="O19">
            <title>Vital Signs (Pulse Rate), 160 Minutes Post-dose</title>
          </group>
          <group group_id="O20">
            <title>Vital Signs (Pulse Rate), 170 Minutes Post-dose</title>
          </group>
          <group group_id="O21">
            <title>Vital Signs (Pulse Rate), 180 Minutes Post-dose</title>
          </group>
          <group group_id="O22">
            <title>Vital Signs (Pulse Rate), 190 Minutes Post-dose</title>
          </group>
          <group group_id="O23">
            <title>Vital Signs (Pulse Rate), 200 Minutes Post-dose</title>
          </group>
          <group group_id="O24">
            <title>Vital Signs (Pulse Rate), 210 Minutes Post-dose</title>
          </group>
          <group group_id="O25">
            <title>Vital Signs (Pulse Rate), 220 Minutes Post-dose</title>
          </group>
          <group group_id="O26">
            <title>Vital Signs (Pulse Rate), 230 Minutes Post-dose</title>
          </group>
          <group group_id="O27">
            <title>Vital Signs (Pulse Rate), 240 Minutes Post-dose</title>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs (Pulse)</title>
          <description>Vital signs (pulse, systolic and diastolic pressure) were measured at pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</description>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="16"/>
                <count group_id="O9" value="16"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="16"/>
                <count group_id="O13" value="16"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="16"/>
                <count group_id="O16" value="16"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="15"/>
                <count group_id="O19" value="15"/>
                <count group_id="O20" value="15"/>
                <count group_id="O21" value="15"/>
                <count group_id="O22" value="15"/>
                <count group_id="O23" value="15"/>
                <count group_id="O24" value="15"/>
                <count group_id="O25" value="15"/>
                <count group_id="O26" value="15"/>
                <count group_id="O27" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="58" upper_limit="98"/>
                    <measurement group_id="O2" value="72" lower_limit="54" upper_limit="90"/>
                    <measurement group_id="O3" value="72" lower_limit="60" upper_limit="95"/>
                    <measurement group_id="O4" value="79" lower_limit="59" upper_limit="101"/>
                    <measurement group_id="O5" value="71" lower_limit="58" upper_limit="89"/>
                    <measurement group_id="O6" value="72" lower_limit="56" upper_limit="94"/>
                    <measurement group_id="O7" value="71" lower_limit="55" upper_limit="86"/>
                    <measurement group_id="O8" value="70" lower_limit="54" upper_limit="86"/>
                    <measurement group_id="O9" value="71" lower_limit="55" upper_limit="86"/>
                    <measurement group_id="O10" value="74" lower_limit="61" upper_limit="89"/>
                    <measurement group_id="O11" value="72" lower_limit="57" upper_limit="86"/>
                    <measurement group_id="O12" value="71" lower_limit="53" upper_limit="90"/>
                    <measurement group_id="O13" value="70" lower_limit="54" upper_limit="91"/>
                    <measurement group_id="O14" value="72" lower_limit="57" upper_limit="88"/>
                    <measurement group_id="O15" value="70" lower_limit="52" upper_limit="86"/>
                    <measurement group_id="O16" value="71" lower_limit="58" upper_limit="91"/>
                    <measurement group_id="O17" value="72" lower_limit="53" upper_limit="97"/>
                    <measurement group_id="O18" value="72" lower_limit="55" upper_limit="98"/>
                    <measurement group_id="O19" value="74" lower_limit="58" upper_limit="93"/>
                    <measurement group_id="O20" value="74" lower_limit="57" upper_limit="100"/>
                    <measurement group_id="O21" value="73" lower_limit="53" upper_limit="91"/>
                    <measurement group_id="O22" value="72" lower_limit="50" upper_limit="90"/>
                    <measurement group_id="O23" value="75" lower_limit="62" upper_limit="90"/>
                    <measurement group_id="O24" value="72" lower_limit="54" upper_limit="97"/>
                    <measurement group_id="O25" value="70" lower_limit="53" upper_limit="96"/>
                    <measurement group_id="O26" value="72" lower_limit="57" upper_limit="96"/>
                    <measurement group_id="O27" value="77" lower_limit="62" upper_limit="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs (Systolic Pressure)</title>
        <time_frame>Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vital Signs (Systolic), - 20 Minutes Pre-dose</title>
          </group>
          <group group_id="O2">
            <title>Vital Signs (Systolic), - 10 Minutes Pre-dose</title>
          </group>
          <group group_id="O3">
            <title>Vital Signs (Systolic), 0 Minutes Pre-dose</title>
          </group>
          <group group_id="O4">
            <title>Vital Signs (Systolic), 10 Minutes Post-dose</title>
          </group>
          <group group_id="O5">
            <title>Vital Signs (Systolic), 20 Minutes Post-dose</title>
          </group>
          <group group_id="O6">
            <title>Vital Signs (Systolic), 30 Minutes Post-dose</title>
          </group>
          <group group_id="O7">
            <title>Vital Signs (Systolic), 40 Minutes Post-dose</title>
          </group>
          <group group_id="O8">
            <title>Vital Signs (Systolic), 50 Minutes Post-dose</title>
          </group>
          <group group_id="O9">
            <title>Vital Signs (Systolic), 60 Minutes Post-dose</title>
          </group>
          <group group_id="O10">
            <title>Vital Signs (Systolic), 70 Minutes Post-dose</title>
          </group>
          <group group_id="O11">
            <title>Vital Signs (Systolic) 80 Minutes Post-dose</title>
          </group>
          <group group_id="O12">
            <title>Vital Signs (Systolic), 90 Minutes Post-dose</title>
          </group>
          <group group_id="O13">
            <title>Vital Signs (Systolic), 100 Minutes Post-dose</title>
          </group>
          <group group_id="O14">
            <title>Vital Signs (Systolic), 110 Minutes Post-dose</title>
          </group>
          <group group_id="O15">
            <title>Vital Signs (Systolic), 120 Minutes Post-dose</title>
          </group>
          <group group_id="O16">
            <title>Vital Signs (Systolic), 130 Minutes Post-dose</title>
          </group>
          <group group_id="O17">
            <title>Vital Signs (Systolic), 140 Minutes Post-dose</title>
          </group>
          <group group_id="O18">
            <title>Vital Signs (Systolic), 150 Minutes Post-dose</title>
          </group>
          <group group_id="O19">
            <title>Vital Signs (Systolic), 160 Minutes Post-dose</title>
          </group>
          <group group_id="O20">
            <title>Vital Signs (Systolic), 170 Minutes Post-dose</title>
          </group>
          <group group_id="O21">
            <title>Vital Signs (Systolic), 180 Minutes Post-dose</title>
          </group>
          <group group_id="O22">
            <title>Vital Signs (Systolic), 190 Minutes Post-dose</title>
          </group>
          <group group_id="O23">
            <title>Vital Signs (Systolic), 200 Minutes Post-dose</title>
          </group>
          <group group_id="O24">
            <title>Vital Signs (Systolic), 210 Minutes Post-dose</title>
          </group>
          <group group_id="O25">
            <title>Vital Signs (Systolic), 220 Minutes Post-dose</title>
          </group>
          <group group_id="O26">
            <title>Vital Signs (Systolic), 230 Minutes Post-dose</title>
          </group>
          <group group_id="O27">
            <title>Vital Signs (Systolic), 240 Minutes Post-dose</title>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs (Systolic Pressure)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="16"/>
                <count group_id="O9" value="16"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="16"/>
                <count group_id="O13" value="16"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="16"/>
                <count group_id="O16" value="16"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="15"/>
                <count group_id="O19" value="15"/>
                <count group_id="O20" value="15"/>
                <count group_id="O21" value="15"/>
                <count group_id="O22" value="15"/>
                <count group_id="O23" value="15"/>
                <count group_id="O24" value="15"/>
                <count group_id="O25" value="15"/>
                <count group_id="O26" value="15"/>
                <count group_id="O27" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" spread="11.5"/>
                    <measurement group_id="O2" value="104" spread="9.4"/>
                    <measurement group_id="O3" value="106" spread="9.1"/>
                    <measurement group_id="O4" value="115" spread="9.7"/>
                    <measurement group_id="O5" value="109" spread="7.9"/>
                    <measurement group_id="O6" value="108" spread="9.4"/>
                    <measurement group_id="O7" value="106" spread="9.8"/>
                    <measurement group_id="O8" value="106" spread="9.6"/>
                    <measurement group_id="O9" value="105" spread="12.1"/>
                    <measurement group_id="O10" value="106" spread="7.9"/>
                    <measurement group_id="O11" value="104" spread="11.0"/>
                    <measurement group_id="O12" value="106" spread="9.7"/>
                    <measurement group_id="O13" value="106" spread="9.9"/>
                    <measurement group_id="O14" value="106" spread="10.7"/>
                    <measurement group_id="O15" value="106" spread="11.4"/>
                    <measurement group_id="O16" value="105" spread="8.9"/>
                    <measurement group_id="O17" value="108" spread="8.0"/>
                    <measurement group_id="O18" value="107" spread="8.4"/>
                    <measurement group_id="O19" value="105" spread="10.7"/>
                    <measurement group_id="O20" value="106" spread="9.6"/>
                    <measurement group_id="O21" value="104" spread="10.2"/>
                    <measurement group_id="O22" value="103" spread="10.7"/>
                    <measurement group_id="O23" value="103" spread="10.9"/>
                    <measurement group_id="O24" value="102" spread="9.2"/>
                    <measurement group_id="O25" value="104" spread="10.8"/>
                    <measurement group_id="O26" value="102" spread="10.6"/>
                    <measurement group_id="O27" value="102" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs (Diastolic Pressure)</title>
        <time_frame>Pre-dose (-20, -10 and 0 min prior to Oraqix administration) and every 10 minutes up to 240 minutes post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vital Signs (Diastolic), - 20 Minutes Pre-dose</title>
          </group>
          <group group_id="O2">
            <title>Vital Signs (Diastolic), - 10 Minutes Pre-dose</title>
          </group>
          <group group_id="O3">
            <title>Vital Signs (Diastolic), 0 Minutes Pre-dose</title>
          </group>
          <group group_id="O4">
            <title>Vital Signs (Diastolic), 10 Minutes Post-dose</title>
          </group>
          <group group_id="O5">
            <title>Vital Signs (Diastolic), 20 Minutes Post-dose</title>
          </group>
          <group group_id="O6">
            <title>Vital Signs (Diastolic), 30 Minutes Post-dose</title>
          </group>
          <group group_id="O7">
            <title>Vital Signs (Diastolic), 40 Minutes Post-dose</title>
          </group>
          <group group_id="O8">
            <title>Vital Signs (Diastolic), 50 Minutes Post-dose</title>
          </group>
          <group group_id="O9">
            <title>Vital Signs Diastolic(), 60 Minutes Post-dose</title>
          </group>
          <group group_id="O10">
            <title>Vital Signs (Diastolic), 70 Minutes Post-dose</title>
          </group>
          <group group_id="O11">
            <title>Vital Signs (Diastolic) 80 Minutes Post-dose</title>
          </group>
          <group group_id="O12">
            <title>Vital Signs (Diastolic), 90 Minutes Post-dose</title>
          </group>
          <group group_id="O13">
            <title>Vital Signs (Diastolic), 100 Minutes Post-dose</title>
          </group>
          <group group_id="O14">
            <title>Vital Signs (Diastolic), 110 Minutes Post-dose</title>
          </group>
          <group group_id="O15">
            <title>Vital Signs (Diastolic), 120 Minutes Post-dose</title>
          </group>
          <group group_id="O16">
            <title>Vital Signs Diastolic(), 130 Minutes Post-dose</title>
          </group>
          <group group_id="O17">
            <title>Vital Signs (Diastolic), 140 Minutes Post-dose</title>
          </group>
          <group group_id="O18">
            <title>Vital Signs (Diastolic), 150 Minutes Post-dose</title>
          </group>
          <group group_id="O19">
            <title>Vital Signs (Diastolic), 160 Minutes Post-dose</title>
          </group>
          <group group_id="O20">
            <title>Vital Signs (Diastolic), 170 Minutes Post-dose</title>
          </group>
          <group group_id="O21">
            <title>Vital Signs (Diastolic), 180 Minutes Post-dose</title>
          </group>
          <group group_id="O22">
            <title>Vital Signs (Diastolic), 190 Minutes Post-dose</title>
          </group>
          <group group_id="O23">
            <title>Vital Signs (Diastolic), 200 Minutes Post-dose</title>
          </group>
          <group group_id="O24">
            <title>Vital Signs (Diastolic), 210 Minutes Post-dose</title>
          </group>
          <group group_id="O25">
            <title>Vital Signs (Diastolic), 220 Minutes Post-dose</title>
          </group>
          <group group_id="O26">
            <title>Vital Signs (Diastolic), 230 Minutes Post-dose</title>
          </group>
          <group group_id="O27">
            <title>Vital Signs (Diastolic), 240 Minutes Post-dose</title>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs (Diastolic Pressure)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="16"/>
                <count group_id="O8" value="16"/>
                <count group_id="O9" value="16"/>
                <count group_id="O10" value="16"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="16"/>
                <count group_id="O13" value="16"/>
                <count group_id="O14" value="16"/>
                <count group_id="O15" value="16"/>
                <count group_id="O16" value="16"/>
                <count group_id="O17" value="16"/>
                <count group_id="O18" value="16"/>
                <count group_id="O19" value="15"/>
                <count group_id="O20" value="15"/>
                <count group_id="O21" value="15"/>
                <count group_id="O22" value="15"/>
                <count group_id="O23" value="15"/>
                <count group_id="O24" value="15"/>
                <count group_id="O25" value="15"/>
                <count group_id="O26" value="15"/>
                <count group_id="O27" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" spread="6.8"/>
                    <measurement group_id="O2" value="60" spread="7.2"/>
                    <measurement group_id="O3" value="63" spread="7.2"/>
                    <measurement group_id="O4" value="69" spread="7.9"/>
                    <measurement group_id="O5" value="63" spread="6.2"/>
                    <measurement group_id="O6" value="64" spread="5.6"/>
                    <measurement group_id="O7" value="62" spread="8.7"/>
                    <measurement group_id="O8" value="62" spread="11.2"/>
                    <measurement group_id="O9" value="62" spread="7.7"/>
                    <measurement group_id="O10" value="62" spread="10.8"/>
                    <measurement group_id="O11" value="62" spread="9.3"/>
                    <measurement group_id="O12" value="64" spread="7.6"/>
                    <measurement group_id="O13" value="63" spread="7.6"/>
                    <measurement group_id="O14" value="63" spread="11.4"/>
                    <measurement group_id="O15" value="60" spread="7.6"/>
                    <measurement group_id="O16" value="62" spread="7.9"/>
                    <measurement group_id="O17" value="62" spread="7.2"/>
                    <measurement group_id="O18" value="63" spread="9.1"/>
                    <measurement group_id="O19" value="63" spread="6.6"/>
                    <measurement group_id="O20" value="60" spread="6.8"/>
                    <measurement group_id="O21" value="60" spread="8.8"/>
                    <measurement group_id="O22" value="61" spread="7.1"/>
                    <measurement group_id="O23" value="60" spread="7.6"/>
                    <measurement group_id="O24" value="59" spread="7.5"/>
                    <measurement group_id="O25" value="57" spread="6.9"/>
                    <measurement group_id="O26" value="57" spread="6.9"/>
                    <measurement group_id="O27" value="60" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECGs (Ventricular Heart Rate)</title>
        <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
        <time_frame>Pre-dose, 1 hour, 2 hour, 4 hour post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ventricular Heart Rate, Pre-dose</title>
          </group>
          <group group_id="O2">
            <title>Ventricular Heart Rate, 1 Hour Post-dose</title>
          </group>
          <group group_id="O3">
            <title>Ventricular Heart Rate, 2 Hour Post-dose</title>
          </group>
          <group group_id="O4">
            <title>Ventricular Heart Rate, 4 Hour Post-dose</title>
          </group>
        </group_list>
        <measure>
          <title>ECGs (Ventricular Heart Rate)</title>
          <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" spread="9.9"/>
                    <measurement group_id="O2" value="70" spread="8.3"/>
                    <measurement group_id="O3" value="71" spread="6.5"/>
                    <measurement group_id="O4" value="74" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECGs (PR Interval)</title>
        <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
        <time_frame>Pre-dose, 1 hour, 2 hour, 4 hour post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PR Interval, Pre-dose</title>
          </group>
          <group group_id="O2">
            <title>PR Interval, 1 Hour Post-dose</title>
          </group>
          <group group_id="O3">
            <title>PR Interval, 2 Hour Post-dose</title>
          </group>
          <group group_id="O4">
            <title>PR Interval, 4 Hour Post-dose</title>
          </group>
        </group_list>
        <measure>
          <title>ECGs (PR Interval)</title>
          <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148" spread="21.1"/>
                    <measurement group_id="O2" value="147" spread="23.7"/>
                    <measurement group_id="O3" value="147" spread="22.4"/>
                    <measurement group_id="O4" value="139" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECGs (QRS Duration)</title>
        <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
        <time_frame>Pre-dose, 1 hour, 2 hour, 4 hour post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>QRS Duration, Pre-dose</title>
          </group>
          <group group_id="O2">
            <title>QRS Duration, 1 Hour Post-dose</title>
          </group>
          <group group_id="O3">
            <title>QRS Duration, 2 Hour Post-dose</title>
          </group>
          <group group_id="O4">
            <title>QRS Duration, 4 Hour Post-dose</title>
          </group>
        </group_list>
        <measure>
          <title>ECGs (QRS Duration)</title>
          <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" spread="5.7"/>
                    <measurement group_id="O2" value="76" spread="4.5"/>
                    <measurement group_id="O3" value="75" spread="7.5"/>
                    <measurement group_id="O4" value="74" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECGs (QT Interval)</title>
        <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
        <time_frame>Pre-dose, 1 hour, 2 hour, 4 hour post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>QT Interval, Pre-dose</title>
          </group>
          <group group_id="O2">
            <title>QT Interval, 1 Hour Post-dose</title>
          </group>
          <group group_id="O3">
            <title>QT Interval, 2 Hour Post-dose</title>
          </group>
          <group group_id="O4">
            <title>QT Interval, 4 Hour Post-dose</title>
          </group>
        </group_list>
        <measure>
          <title>ECGs (QT Interval)</title>
          <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376" spread="22.5"/>
                    <measurement group_id="O2" value="384" spread="19.3"/>
                    <measurement group_id="O3" value="383" spread="19.0"/>
                    <measurement group_id="O4" value="379" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECGs (QTcB Interval)</title>
        <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
        <time_frame>Pre-dose, 1 hour, 2 hour, 4 hour post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>QTcB Interval, Pre-dose</title>
          </group>
          <group group_id="O2">
            <title>QTcB Interval, 1 Hour Post-dose</title>
          </group>
          <group group_id="O3">
            <title>QTcB Interval, 2 Hour Post-dose</title>
          </group>
          <group group_id="O4">
            <title>QTcB Interval, 4 Hour Post-dose</title>
          </group>
        </group_list>
        <measure>
          <title>ECGs (QTcB Interval)</title>
          <description>Ventricular heart rate, PR interval, QRS duration, QT interval, and QTcB intervals were calculated.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412" spread="19.0"/>
                    <measurement group_id="O2" value="413" spread="21.9"/>
                    <measurement group_id="O3" value="415" spread="18.6"/>
                    <measurement group_id="O4" value="419" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adverse Events</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gagging</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tooth pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The subject study was a post-approval requirement related to the approval of NDA 21-451 to evaluate the pharmacokinetics and safety of the Oraqix gel in pediatric patients. As the purpose of the study was solely to fulfill a post approval regulatory requirement, the information is considered proprietary to the sponsor (Dentsply International, Inc.) and disclosure by the Investigators to any third party (unless such disclosure was required by government regulations or laws) was prohibited.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tegwyn H. Brickhouse, DDS, PhD</name_or_title>
      <organization>Virginia Commonwealth University, School of Dentistry</organization>
      <phone>(804) 827-2699</phone>
      <email>thbrickhouse@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

